Ramelteon (TAK-375) CAS 196597-26-9 Tsafta > 99.5% (HPLC)

Ramelteon (CAS: 196597-26-9) Hukumar Abinci da Magunguna ta Amurka (FDA) ta fara amincewa da ita a ranar 22 ga Yuli, 2005, sannan Hukumar Kula da Magunguna da Magunguna (PMDA) ta amince da ita a ranar 16 ga Afrilu, 2010. An haɓaka shi kuma kasuwa kamar Rozerem® ta Takeda,za a iya amfani da shi don magance rashin barci tare da wahalar yin barci, kuma yana da tabbataccen tasiri akan rashin barci mai tsanani da rashin barci na gajeren lokaci.Wannan samfurin na iya zaɓin kunna nau'in 1 da nau'in 2 masu karɓa na melatonin (MT1, MT2), ƙara jinkirin bacci (SWS) da saurin motsin ido (REW), don haka rage rashin bacci.Ramelteamide shine magani na farko wanda ba ya kamu da rashin bacci wanda baya ƙarƙashin kulawa ta musamman.Wannan samfurin agonist mai karɓar melatonin ne.Yana da alaƙa mai girma tare da masu karɓar melatonin MT1 da MT2, kuma yana da takamaiman kuma cikakkiyar tasirin agonist akan masu karɓar MT1 da MT2, amma baya hulɗa da mai karɓar MT3.Bugu da ƙari, ba ya ɗaure masu karɓa na neurotransmitter irin su GABA receptor complexes, kuma baya tsoma baki tare da ayyukan yawancin enzymes a cikin wani yanki.Sabili da haka, zai iya guje wa ɓarna da ke tattare da magungunan GABA (wanda zai iya haifar da hadarin mota, faduwa da karaya).Da dai sauransu) da kuma shan miyagun ƙwayoyi da dogaro.Ana samun Rozerem® azaman kwamfutar hannu mai rufin fim don amfani da baki, mai ɗauke da 8 MG na Ramelteon kyauta.Adadin manya da aka ba da shawarar shine 8 MG da aka ɗauka a cikin mintuna 30 na zuwa barci.